233 related articles for article (PubMed ID: 37084735)
1. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
Jana S; Brahma S; Arora S; Wladyka CL; Hoang P; Blinka S; Hough R; Horn JL; Liu Y; Wang LJ; Depeille P; Smith E; Montgomery RB; Lee JK; Haffner MC; Vakar-Lopez F; Grivas P; Wright JL; Lam HM; Black PC; Roose JP; Ryazanov AG; Subramaniam AR; Henikoff S; Hsieh AC
Cancer Cell; 2023 May; 41(5):853-870.e13. PubMed ID: 37084735
[TBL] [Abstract][Full Text] [Related]
2. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
4. Repression of eEF2K transcription by NF-κB tunes translation elongation to inflammation and dsDNA-sensing.
Bianco C; Thompson L; Mohr I
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22583-22590. PubMed ID: 31636182
[TBL] [Abstract][Full Text] [Related]
5. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
6. Arid1a regulates bladder urothelium formation and maintenance.
Guo C; Zhang Y; Tan R; Tang Z; Lam CM; Ye X; Wang Z; Li X
Dev Biol; 2022 May; 485():61-69. PubMed ID: 35283102
[TBL] [Abstract][Full Text] [Related]
7. Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability.
Liu X; Li Z; Wang Z; Liu F; Zhang L; Ke J; Xu X; Zhang Y; Yuan Y; Wei T; Shan Q; Chen Y; Huang W; Gao J; Wu N; Chen F; Sun L; Qiu Z; Deng Y; Wang X
Cancer Res; 2022 Mar; 82(5):791-804. PubMed ID: 34987057
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase.
Johanns M; Pyr Dit Ruys S; Houddane A; Vertommen D; Herinckx G; Hue L; Proud CG; Rider MH
Cell Signal; 2017 Aug; 36():212-221. PubMed ID: 28502587
[TBL] [Abstract][Full Text] [Related]
9. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract][Full Text] [Related]
10. SWI/SNF Alterations in Squamous Bladder Cancers.
Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
[TBL] [Abstract][Full Text] [Related]
11. The emerging roles of ARID1A in tumor suppression.
Wu RC; Wang TL; Shih IeM
Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic significance of ARID1A mutation in bladder cancer.
Conde M; Frew IJ
Neoplasia; 2022 Sep; 31():100814. PubMed ID: 35750014
[TBL] [Abstract][Full Text] [Related]
13. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
14. Investigating Eukaryotic Elongation Factor 2 Kinase/Eukaryotic Translation Elongation Factor 2 Pathway Regulation and Its Role in Protein Synthesis Impairment during Disuse-Induced Skeletal Muscle Atrophy.
Vilchinskaya N; Lim WF; Belova S; Roberts TC; Wood MJA; Lomonosova Y
Am J Pathol; 2023 Jun; 193(6):813-828. PubMed ID: 36871751
[TBL] [Abstract][Full Text] [Related]
15. ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression.
Luo Q; Wu X; Chang W; Zhao P; Zhu X; Chen H; Nan Y; Luo A; Zhou X; Su D; Jiao W; Liu Z
Cancer Res; 2020 Feb; 80(3):406-417. PubMed ID: 32015157
[TBL] [Abstract][Full Text] [Related]
16. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
17. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
18. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
19. 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.
Chen Z; Gopalakrishnan SM; Bui MH; Soni NB; Warrior U; Johnson EF; Donnelly JB; Glaser KB
J Biol Chem; 2011 Dec; 286(51):43951-43958. PubMed ID: 22020937
[TBL] [Abstract][Full Text] [Related]
20. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Balbás-Martínez C; Rodríguez-Pinilla M; Casanova A; Domínguez O; Pisano DG; Gómez G; Lloreta J; Lorente JA; Malats N; Real FX
PLoS One; 2013; 8(5):e62483. PubMed ID: 23650517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
